NASDAQ:TENX Tenax Therapeutics (TENX) Stock Price, News & Analysis $7.20 -0.10 (-1.37%) Closing price 02/14/2025 03:58 PM EasternExtended Trading$7.22 +0.02 (+0.29%) As of 02/14/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Tenax Therapeutics Stock (NASDAQ:TENX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tenax Therapeutics alerts:Sign Up Key Stats Today's Range$7.11▼$7.4550-Day Range$5.49▼$7.7652-Week Range$2.77▼$7.89Volume14,197 shsAverage Volume38,973 shsMarket Capitalization$24.55 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company OverviewTenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Read More… Tenax Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreTENX MarketRank™: Tenax Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 717th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingTenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenax Therapeutics has received no research coverage in the past 90 days.Read more about Tenax Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tenax Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.29% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenax Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.29% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenax Therapeutics has recently decreased by 2.56%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News SentimentN/A Search Interest2 people have searched for TENX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Tenax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.67% of the stock of Tenax Therapeutics is held by institutions.Read more about Tenax Therapeutics' insider trading history. Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TENX Stock News HeadlinesLeerink Partnrs Brokers Reduce Earnings Estimates for TENXFebruary 8, 2025 | americanbankingnews.comTenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 31, 2025 | globenewswire.comForget morning trades: Here’s when real money movesWhen 12pm Eastern rolls around… Something really special happens. It’s the first hour of the day that the overseas markets are closed… And it’s the FIRST time that we can see Wall Street trading freely on their own – without the noise from the international markets… That’s why we see so many opportunities during the Genesis Hour. And anyone who can spot stocks breaking out during the 12 pm Genesis Hour can then jump in ahead of what could be the next big move… Intrigued? You should be! Because it’s one of the most exciting, little-known revelations I’ve uncovered in my 40+ years trading the markets. If you’d like to join him for a deeper dive… February 17, 2025 | Diversified Trading Institute (Ad)Tenax Therapeutics, Inc. Common Stock (TENX) Insider ActivityJanuary 28, 2025 | nasdaq.comTenax Therapeutics Appoints Gillian Andor Vice President, Clinical OperationsJanuary 22, 2025 | markets.businessinsider.comWill Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely?December 6, 2024 | finance.yahoo.comTenax Therapeutics Appoints Interim CFO Thomas McGauleyDecember 4, 2024 | tipranks.comTenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)November 15, 2024 | seekingalpha.comSee More Headlines TENX Stock Analysis - Frequently Asked Questions How have TENX shares performed this year? Tenax Therapeutics' stock was trading at $6.19 on January 1st, 2025. Since then, TENX shares have increased by 16.3% and is now trading at $7.20. View the best growth stocks for 2025 here. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings results on Tuesday, August, 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping analysts' consensus estimates of ($1.99) by $0.16. When did Tenax Therapeutics' stock split? Shares of Tenax Therapeutics reverse split on Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tenax Therapeutics' major shareholders? Top institutional investors of Tenax Therapeutics include Janus Henderson Group PLC (4.89%), Vestal Point Capital LP (1.62%), ADAR1 Capital Management LLC (1.02%) and Millennium Management LLC (0.79%). View institutional ownership trends. How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/13/2024Today2/17/2025Next Earnings (Estimated)3/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TENX CUSIPN/A CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees9Year Founded1967Price Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+122.2%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,710,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.00% Return on Assets-42.65% Debt Debt-to-Equity RatioN/A Current Ratio38.95 Quick Ratio38.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.15 per share Price / Book0.27Miscellaneous Outstanding Shares3,410,000Free Float3,283,000Market Cap$24.55 million OptionableNot Optionable Beta2.14 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TENX) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.